bevacizumab,panitumumab
roche,amgen,takeda
['biomarker', 'panitumumab', 'paradigm']
#asco23 efficacy of panitumumab in patients with left-sided disease, mss/msi-l, and ras/braf wt: a biomarker study of the phase iii paradigm trial based on baseline plasma ctdna analysis:
rasmt 7.2% brafmt 10.6%
msi-h 2.7% mos for left-side with msi-h or ras/brafmt+
pan 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm